Redeye is a leading investment banking boutique focusing on small and
medium sized growth companies in the Nordic Countries.
We provide Corporate Broking, Corporate Finance, Equity Research,
Investor Services and Media Services.
NeuroVive - Rights issue
Redeye advised, structured and implemented the guarantee consortia in NeuroVive´s rights issue announced 14 March 2012 amounting to SEK 64.8m, jointly with Sedermera Fondkommission. The rights issue is 85% guaranteed.
The Board of Directors of NeuroVive has resolved, subject to the approval by the General Meeting, to conduct a new share issue with preferential rights for the shareholders of the company. The purpose of the rights issue is to strengthen NeuroVive's financial position and thereby enable the fulfillment of the company's research area mitochondrial medicine. Three existing shares in Genovis entitle to subscription for one new share. The subscription price is SEK 13.00 per share, corresponding to total issue proceeds of a maximum of SEK 64.8m, before transaction costs and compensation to guarantee providers. The subscription period will be from 18 April up to and including 4 May 2012. An Extraordinary General Meeting will be held on 2 April 2012 for the approval of the rights issue.
NeuroVive Pharmaceutical AB was founded in 2000 as a subsidiary of Maas Biolab, LLC (founded in 1997) with the aim of commercializing work on developing cyclosporine-based drugs for acute conditions and illnesses affecting the brain and central nervous system (CNS). NeuroVive went public in 2008 with an IPO on the Swedish AktieTorget.
Genovis – Rights issue
Redeye advised, structured and implemented the guarantee consortia in Genovis´ rights issue announced 20 February 2012 amounting to SEK 12.1m. The rights issue is 100% guaranteed.
The Board of Directors of Genovis has resolved to conduct a new share issue with preemptive rights for the shareholders of the company. Subscription commitments amount to 22.3% of the subscription amount. The rights issue is guaranteed by Mikael Lönn and LMK Ventures. Two existing shares in Genovis entitle to subscription for one new share. The subscription price is SEK 3.50 per share, corresponding to total issue proceeds of a maximum of approx. SEK 12.1m, before transaction costs. The subscription period will be from 25 April up to and including 10 May 2012.
Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The second consists of nanotechnology in new contrast agents and focuses on design, production and characterization of nanostructures as contrast agents in medical imaging.
Genovis shares are listed on the First North OMX Nordic Exchange.